tuneTypical Dose
Some soreness studies used 300 mg three times daily, but the evidence is too inconsistent for a strong generic recommendation
Digestive Enzyme
Bromelain
Bromelain
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Claimed effects are usually framed over days to weeks, but the literature is inconsistent.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Bromelain has limited, formulation-dependent human evidence for postoperative inflammation and selected GI-inflammatory contexts, but the data do not justify broad pain or sports-recovery claims.
Bromelain is often sold for inflammation, recovery, sinus relief, and joint support. The problem is that the human evidence is mixed, often old, and frequently entangled with oral enzyme combinations rather than bromelain alone. Some positive signals exist in niche contexts, including a modern ulcerative-colitis RCT and a 2025 postoperative systemic-enzyme study, but neither supports broad anti-inflammatory or sports-recovery marketing for generic bromelain products.
Bromelain is a proteolytic enzyme mixture from pineapple. Proposed mechanisms around edema, inflammatory mediators, and protein digestion are biologically plausible, but clinical translation remains inconsistent and low confidence.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Inconsistent and low-confidence symptom benefit for pain or swelling
Secondary Outcomes
- No dependable evidence for DOMS reduction
- Weak support for broad anti-inflammatory claims
Safety
Contraindications and Interactions
Contraindications
- Pineapple allergy
- Upcoming surgery
Side effects
- GI upset
- Nausea
- Allergy symptoms
Interactions
- Anticoagulant or antiplatelet strategies
Avoid if
- You have pineapple allergy
- You are using it as a substitute for evidence-based pain or inflammation care
Evidence
Study-level References
brm-SRC-001Narrative review of clinical studies
Sourceopen_in_newBrien S, Lewith G, Walker A, et al. Bromelain as a Treatment for Osteoarthritis. A review of clinical studies. Evid Based Complement Alternat Med. 2004;1(3):251-257. doi:10.2165/00007256-200535120-00001. PMID:15841258.
Population: Adults with osteoarthritis across available bromelain clinical studies.
Dose protocol: Mixed bromelain and enzyme-study protocols
Key findings: Osteoarthritis evidence remained inconclusive.
Notes: Helpful mostly as a reality check on the evidence base.
Paper content
This review is mainly useful because it shows how long bromelain has been marketed for joint pain without developing a strong human evidence base. Some clinical signals exist, but the evidence is inconsistent and often mixed with oral enzyme combinations rather than bromelain alone.
brm-SRC-002Randomized controlled pilot trial
Sourceopen_in_newWalker AF, Bundy R, Hicks SM, Middleton RW. Bromelain as an adjunctive treatment for moderate-to-severe osteoarthritis of the knee. A randomized placebo-controlled pilot study. QJM. 2002;95(12):843-850. doi:10.1080/15622970601071556. PMID:17121765.
Population: Adults with moderate-to-severe knee osteoarthritis.
Dose protocol: Pilot placebo-controlled osteoarthritis trial
Key findings: Possible symptom benefit, but only preliminary.
Notes: Too weak for strong arthritis claims.
Paper content
This pilot knee-osteoarthritis trial is often cited in bromelain marketing, but it remains preliminary and insufficient to support a strong arthritis claim. It is useful mainly as an example of why the evidence base stayed low confidence despite long-standing commercial interest.
brm-SRC-003Randomized controlled trial
Sourceopen_in_newStone MB, Merrick MA, Ingersoll CD, Edwards JE. Preliminary comparison of bromelain and ibuprofen for delayed onset muscle soreness management. Clin J Sport Med. 2002;12(6):373-378. PMID:12466693.
Population: Healthy adults with exercise-induced delayed onset muscle soreness of the elbow flexors.
Dose protocol: 300 mg three times daily in a DOMS protocol
Key findings: No convincing superiority over placebo for DOMS management.
Notes: Important negative study for recovery framing.
Paper content
This trial matters because it pushes back against common recovery marketing. Bromelain did not establish a convincing advantage over placebo for delayed-onset muscle soreness, which makes broad sports-recovery claims much weaker than many labels suggest.
brm-SRC-004Randomized, triple-blind, placebo-controlled trial.
Sourceopen_in_newDelgarm P, Mokhtare M, Ebrahimi Daryani N, Abolghasemi J, Rahideh ST. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis. Sci Rep. 2025;15(1):42799. doi:10.1038/s41598-025-26975-1. PMID:41315628.
Population: Adults with mild-to-moderate ulcerative colitis.
Dose protocol: 400 mg/day bromelain for 8 weeks in mild-to-moderate ulcerative colitis
Key findings: Significantly reduced disease activity (SCCAI) compared to placebo, though quality of life was not significantly affected.
Notes: First well-controlled RCT for bromelain in IBD. Adds a credible modern data point beyond traditional pain and swelling claims.
Paper content
This triple-blind RCT tested 400 mg/day bromelain for 8 weeks in 70 adults with mild-to-moderate ulcerative colitis. The bromelain group showed a significantly greater reduction in disease activity (SCCAI) compared to placebo. Quality of life did not significantly differ between groups. The study provides the first well-controlled human evidence for bromelain in inflammatory bowel disease, a new therapeutic context beyond the traditional pain and swelling claims. The finding is limited by a single-center design and the disconnect between disease activity improvement and quality of life, but it adds a credible modern data point for bromelain as an adjunctive anti-inflammatory agent in gut inflammation.
brm-SRC-005Randomized, double-blind, placebo- and active-controlled clinical trial
Sourceopen_in_newSuryawanshi A, Patkar H, Aute S, Rathi PC, Rathi CL, Risbud SP, Ganu GP. Systemic enzyme therapy for postoperative inflammation and wound healing after orthopedic surgery: a randomized, placebo and active controlled clinical study. Sci Rep. 2025;15(1):34336. doi:10.1038/s41598-025-16747-2. PMID:41038853.
Population: Adults recovering from orthopedic surgery.
Dose protocol: Bromelain-containing systemic enzyme tablets versus comparator enzyme formulation or placebo for 7 days after orthopedic surgery.
Key findings: Significant reductions in postoperative pain, inflammation, CRP, ESR, erythema, and tenderness versus placebo, with lower analgesic use.
Notes: Useful supportive-care study, but it tested a multi-enzyme product with strong industry involvement rather than bromelain alone.
Paper content
This 7-day randomized, double-blind postoperative study compared EnMax, a bromelain-containing systemic enzyme formulation, with both placebo and an active comparator after orthopedic surgery. EnMax improved pain, inflammation, CRP, ESR, erythema, local irritation, discharge, and tenderness, and it reduced analgesic use without reported adverse events. The signal is supportive but not clean bromelain-alone evidence because the tested product was a multi-enzyme formulation and several authors had direct company ties. It is best used as formulation-specific supportive-care evidence rather than proof that generic bromelain supplements accelerate recovery after surgery.